ExodusPoint Capital Management’s IGM Biosciences IGMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-71,503
Closed -$491K 1821
2024
Q2
$491K Buy
71,503
+51,180
+252% +$438K ﹤0.01% 1212
2024
Q1
$196K Buy
+20,323
New +$236K ﹤0.01% 1358
2023
Q4
Sell
-453,898
Closed -$3.79M 1732
2023
Q3
$3.79M Buy
+453,898
New +$3.85M 0.04% 449
2023
Q2
Sell
-59,650
Closed -$820K 2037
2023
Q1
$820K Buy
59,650
+12,570
+27% +$260K 0.01% 1204
2022
Q4
$801K Buy
47,080
+21,595
+85% +$432K 0.01% 1019
2022
Q3
$580K Buy
+25,485
New +$515K 0.01% 1315
2022
Q2
Sell
-10,728
Closed -$287K 2154
2022
Q1
$287K Buy
10,728
+1,698
+19% +$31.6K ﹤0.01% 1780
2021
Q4
$265K Buy
9,030
+3,903
+76% +$194K ﹤0.01% 1711
2021
Q3
$337K Sell
5,127
-1,666
-25% -$127K ﹤0.01% 1570
2021
Q2
$565K Buy
6,793
+391
+6% +$29K 0.01% 1306
2021
Q1
$491K Buy
+6,402
New +$583K 0.01% 1381
2020
Q4
Sell
-4,295
Closed -$317K 2139
2020
Q3
$317K Buy
+4,295
New +$254K 0.01% 1254
2020
Q2
Sell
-29,834
Closed -$1.68M 1887
2020
Q1
$1.68M Buy
+29,834
New +$1.31M 0.09% 213

Other funds holding IGMS

ExodusPoint Capital Management's IGMS Position: Q3 2024 in Review

ExodusPoint Capital Management sold out of IGM Biosciences (IGMS) in Q3 2024, closing a stake of 71,503 shares — an estimated $491K sold.

ExodusPoint Capital Management first reported a position in IGMS in Q1 2020 and held it in 13 quarters. The position peaked at $3.79M in Q3 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q3 2024.

  • ExodusPoint Capital Management reported no remaining IGM Biosciences position as of Q3 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 71,503 IGM Biosciences shares in Q3 2024, an estimated $491K.
  • ExodusPoint Capital Management first reported a position in IGM Biosciences in Q1 2020 and held it in 13 quarters.
  • ExodusPoint Capital Management's IGM Biosciences position peaked at $3.79M in Q3 2023.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.